Global drug development and international harmonization: The emergence of China as a world pharmaceutical player

被引:4
作者
Kaitin, KI [1 ]
机构
[1] Tufts Univ, Tufts Ctr Study Drug Dev, Boston, MA 02111 USA
来源
DRUG INFORMATION JOURNAL | 1998年 / 32卷
关键词
China; drug development; pharmaceutical innovation; regulatory reform; multinational pharmaceutical industry;
D O I
10.1177/00928615980320S103
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The People's Republic of China represents a rapidly expanding pharmaceutical market with the potential to become a major player in pharmaceutical development. As the Chinese government moves forward in its campaign to build a modern pharmaceutical industry, it is instructive to examine issues in global drug development. This paper reviews various factors that have an impact on new drug development, including time and cost estimates for bringing a new product to market, and considers several global initiatives designed to facilitate pharmaceutical innovation.
引用
收藏
页码:1187S / 1191S
页数:5
相关论文
共 7 条
[1]  
BRYANT R, 1997, SCRIP MAGAZINE SEP, V60, P58
[2]   SUCCESS RATES FOR NEW DRUGS ENTERING CLINICAL-TESTING IN THE UNITED-STATES [J].
DIMASI, JA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) :1-14
[3]   COST OF INNOVATION IN THE PHARMACEUTICAL-INDUSTRY [J].
DIMASI, JA ;
HANSEN, RW ;
GRABOWSKI, HG ;
LASAGNA, L .
JOURNAL OF HEALTH ECONOMICS, 1991, 10 (02) :107-142
[4]  
Kaitin K I, 1997, Am J Ther, V4, P167, DOI 10.1097/00045391-199705000-00002
[5]  
KAITIN KI, 1997, DRUG INF J, V31, P27
[6]  
WONG E, 1997, DRUG INF J, V31, P93
[7]  
1997, HLTH HORIZONS AUT, P10